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Government healthcare expenditure is rising in Korea, and the costs incurred by patients
in Korea exceed those incurred by patients in other Organization for Economic Co-operation
and Development countries. Despite the increasing health expenditure, patient demand for
services is increasing as well, so it is now becoming recognized that cancer care needs to
be balanced. The most important measure in cancer care optimization is to provide high-
quality care while keeping costs sustainable. The Korean Cancer Association considers the
current situation of cancer therapy in Korea the foremost issue, which has led to the imple-
mentation of the nationwide ‘Right Decisions in Cancer Care’ initiative. This initiative is
based on the concepts of medical professionalism in that it should be led by physicians
working in the field of oncology, that education should be offered to patients and clinicians,
and that it should influence healthcare policy. In this article, we introduce the nationwide
‘Right Decision in Cancer Care’ initiative and highlight the five initial items on its agenda.
The agenda is open to expansion and update as the medical environment evolves and addi-
tional clinical evidence becomes available.
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Korea implemented a national healthcare system (National
Health Insurance, NHI) in 1977, which expanded to the 
entire Korean population in 1989. By 2016, the NHI covered
97.1% of the population [1]. The top three causes of death in
Korea are cancer, heart disease, and cerebrovascular disease
[2]. Copayments for hospital fees for these diseases or rare
diseases are 5% as compared with 20%-30% for other dis-
eases. Because of this support from the government and a
well-developed cancer screening policy, which started in the
1980s, the cancer survival rate in Korea has been increasing
and the cancer incidence rate has been decreasing since 2011
[3].
Government healthcare expenditure is rapidly rising in
Korea, having increased from 5.4% of the gross domestic
product in 2008-2013 to 7.3% in 2013-2018 and further to 8.1%
in 2019; this is only slightly lower than the average in other
Organization for Economic Co-operation and Development
(OECD) countries, which is 8.8% [4]. The portion of health-
care costs borne by the patient is also high in Korea (33.7%
in 2017) relative to that in other OECD countries (Fig. 1A).
As the gross domestic product has increased in Korea, so too
has public spending on health expenditure (Fig. 1A) [5,6].
However, out-of-pocket payments by patients have not 
decreased in proportion to this rise in public spending [6]
(Fig. 1B). Out-of-pocket expenses are the costs of medical care
that are not covered by insurance and that one pays for on
their own. Fig. 2 shows out-of-pocket spending relative to
final household consumption in 2017. Although Korea is
classified as a high-income country by the World Bank, out-
of-pocket spending is still high, at 34% of healthcare expen-
ditures compared to an average of 22% in other high-income
countries [4]. Across OECD countries, an average of about
3% of total household spending is on healthcare-related
goods and services, with Korea ranking near the top (5.6%,
red arrow in Fig. 2) [4,7]. The share of household consump-
tion spent on health care provides an aggregate assessment
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Fig. 1.  (A) Current health expenditure in Korea and its components in million constant US dollar, created from the database
of the website of the World Health Organization, Global Health Expenditure Database. Source: http://apps.who.int/
nha/database/country_profile/Index/en [5,6]. (B) Gross domestic product, public spending, and out-of-pocket expenditure
in Korea. As the gross domestic product has increased in Korea, so too has public spending on healthcare. However, out-of-
pocket expenditure has not decreased in proportion to the rise in public spending. CHE, current healthcare expenditure;
GDP, gross domestic product. Source: World Health Organization, Global Health Expenditure. http://apps.who.int/nha/
database/country_profile/Index/en [6].
of the financial burden of out-of-pocket expenditures, which
can overwhelm poor house-holds that have to pay for long-
term treatment for chronic diseases such as cancer. 
This phenomenon may be partly explained by the demand
for many different types of treatment by patients, beyond
standard care. The immediate availability of diverse private
insurance products, which offer broad coverage of treatment
costs, has accentuated this demand. There are two types of
private insurance, fixed-payment insurance, and variable
payment insurance. Unlike fixed-payment insurance, vari-
able-payment insurance, which is sometimes also referred to
as actual payment insurance, is basically a fee-for-service
health plan that reimburses up to 90% of the medical expen-
diture as patients consume health-related services. Hence,
many people in Korea have variable-payment insurance with
or without fixed-payment private insurance. In 2017, 66% of
people in Korea were covered by variable-payment insur-
ance [8]. Small and medium-sized cancer care hospitals,
which accommodate patients who are being treated or who
have been treated with radiotherapy or chemotherapy, offer
patients various supportive care services. The desires and
needs of patients who want more supportive care are gener-
ally fulfilled by these services. However, patients are also 
offered alternative therapies, including mistletoe, selenium,
high-dose vitamin C, and hyperthermia, for example, and
these practices have been subject to extensive litigation bet-
ween private insurance companies who want to pay less and
patients who want greater coverage. In 2018, the Financial
Supervisory Service (FSS) in Korea announced guidelines
clarifying the necessary components of cancer care and stip-
ulated their coverage as part of private health insurance [9].
The intention was to reduce future disagreement between
patients and private insurance companies regarding indem-
nity payments.
In 2018, the number of patients who received government
reimbursement reached 1,140,000 and the expenditure for
cancer care was KRW 7.5 trillion or 24% of the total expendi-
ture for the 12 most common chronic diseases [10]. This
amount represents 9.6% of the total reimbursement reported
by the NHI and the Health Insurance Review & Assessment
Service (HIRA). However, it is doubtful whether the quality
of cancer care is increasing in parallel with the escalating
healthcare costs. As the costs of treatment and patient 
demand for services continue to escalate, it is clear that can-
cer care needs to be optimized. The key to optimizing care is
to balance the provision of quality cancer care with sustain-
able costs. It is currently the duty of medical professionals to
achieve this goal. They must set clear standards of care as
well as educate patients and clinicians. It is not politicians or
vendors who must set new standards of care, but medical
professionals who can connect patient-oriented values and
medical practice.
As a first step to achieving this goal, it is important to sys-
tematically measure the effects of treatment, and evaluate 
patient reported outcomes. Clinical practice should prioritize
high-value care based on high-quality evidence. Good meas-
ures should be able to differentiate high-quality care from
low-quality care, and should provide insight whether the
healthcare providers support good practices. Also, an eval-
uation system should be able to incentivize higher-quality
care by adopting alternative reimbursement mechanisms, if
needed. The Korean government is primarily focused on 
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Fig. 2.  Out-of-pocket spending relative to final household consumption in 2017 (or the nearest year). Across Organisation
for Economic Co-operation and Development (OECD) countries, about 3% of total household spending is on healthcare
goods and services. Korea ranks near the top of all OECD countries with spending of 5.6% (red arrow), behind Switzerland
(7%). Countries such as Switzerland and The Netherlands have compulsory private health insurance schemes that are sup-
ported by public subsidies and laws on the scope and depth of coverage [7].
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expanding healthcare coverage for cancer and other diseases,
while medical fees are fixed at low prices [11]. This generates
pressure on health-care providers who need to balance costs
and reimbursement. As a result, providers may prioritize
high-frequency practices rather than high-value ones. Factors
such as staffing, interdisciplinary communication, and sup-
portive infra-structure should also be considered when eval-
uating the outcomes that matter to patients [12]. Hence, a
well-defined assessment system should be able to motivate
clinicians to improve care delivery, not just press them to
conform to strict reimbursement criteria.
This current situation in cancer care in Korea was identi-
fied as the foremost issue by the Korean Cancer Association
(KCA), which led to the implementation of the nationwide
‘Right Decision in Cancer Care’ initiative. The United States
National Quality Forum (NCF) on cancer made 10 recom-
mendations to improve the quality of cancer care and correct
problems in healthcare services. It called for major revisions
to healthcare delivery, clinician education and training, and
quality improvement in cancer care in the United States [13].
The KCA is composed of multidisciplinary specialists from
various cancer-related fields [14]. Inspired by the Choosing
Wisely Campaign in the United States, a task force was 
organized under the KCA Review Committee, and the idea
to develop a nationwide campaign was approved by the
KCA Board of Directors in May 2019. This accords with the
global movement aimed at using medical resources more
wisely and providing patients with the best outcomes by 
applying evidence-based, necessary treatments and encour-
aging the medical society to reduce low-value practice [15-
18]. The initiative seeks to address several widespread
problems associated with the underuse, overuse, or misuse
of healthcare, and the authors call for dedicated efforts by
clinicians towards education and training of the patients, and
towards better health delivery, evaluation, and reimburse-
ment for  medical services.
Potential items to be included in the initiative were con-
sidered after reviewing the topics the Review Committee had
covered over the last 3 years. The committee chose five items
for the agenda, as follows.
(1) Do not delay palliative care in advanced cancer pati-
ents. Patients should ask how palliative care can be inte-
grated with their course of treatment. In patients diagnosed
with advanced cancer, end-of-life care should always be con-
sidered as part of the treatment plan. Sometimes cancer pati-
ents with advanced-stage disease are forced to choose bet-
ween active anticancer therapy and palliative care services,
but there is compelling evidence that early referral to pallia-
tive care even in the midst of active anticancer treatment sig-
nificantly decreases the symptom burden and may also
increase the survival of patients with advanced lung cancer
[19]. Several prospective randomized clinical trials have eval-
uated early integration of palliative care with standard 
oncologic care, and the American Society of Clinical Oncol-
ogy incorporated this into their clinical practice guidelines
updated in 2017. They strongly recommended that patients
with advanced cancer should be referred to an inter-discipli-
nary palliative care team early in the disease course, along-
side active anticancer treatment [20]. Additionally, patient
protections and the Affordable Care Act in the United States
brought forward end-of-life care as an important issue in
cancer care, and asserted the necessity of making hospice
service more broadly available to patients with serious ill-
nesses including cancer [13,21].
(2) Pay attention to pain control in cancer patients. Patients
should be aware of their pain symptoms and discuss these
with medical staff. It is important to check whether cancer-
related pain is managed appropriately. Both clinicians and
patients should be educated to dispel misconceptions related
to cancer pain. Although the pain score has been used as the
“fifth vital sign” since 1996, many cancer patients suffer from
significant pain due to underuse or avoidance of cancer-
associated pain control. Pain was reported to affect up to 64%
of cancer patients, and 43% of these patients felt that their
pain control was inappropriate; many barriers to adequate
pain control, including societal, regulatory, clinician, patient,
and socioeconomic conditions have been identified [22,23].
Therefore, the policy for controlling cancer pain control
should be comprehensive, entailing medical management,
psychosocial support, education of the patient and caregiver,
and interventional therapy, including radiotherapy.
(3) Do not use hyperthermia alone in treating cancer. If 
hyperthermia is proposed as a single treatment, ask your
doctor how hyperthermia works in ameliorating symptoms
or treating your cancer. Hyperthermia as a single treatment
is not recommended for the treatment of cancer. In addition, 
hyperthermia does not have clinical effects as adjuvant ther-
apy following surgery [24,25]. However, there is some clini-
cal evidence supporting hyperthermia for locally advanced,
unresectable solid tumors in combination with radiotherapy
[26].
(4) Use brachytherapy appropriately for patients with uter-
ine cancer. If you have uterine cancer or uterine cervical can-
cer, ask your doctor(s) if brachytherapy is needed in the
course of treatment. For uterine cancer, brachytherapy should
be used with or without external beam radiotherapy (EBRT),
as appropriate. For cervical cancer, brachytherapy is an 
essential component of radiotherapy; the adoption of inten-
sity-modulated radiotherapy or stereotactic radiotherapy 
instead of brachytherapy is associated with decreased sur-
vival rates in patients with cervical cancer [27,28]. For endo-
metrial cancer, EBRT should not be routinely used as adju-
vant radiotherapy in patients with early stage cancer if bra-
chytherapy is considered adequate. EBRT is associated with
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a higher rate of pelvic organ complications, and is more time-
and cost-intensive than brachytherapy [29]. Brachytherapy
is an example of a high-value practice that is underestimated
by health providers due to its low relative value unit and low
medical price in Korea. Brachytherapy is currently available
in a limited number of hospitals in Korea [30].
(5) Consult a medical specialist when considering travel-
ling abroad for carbon ion particle therapy. If a patient 
enquires about carbon ion particle therapy, the clinician
should refer the patient to an appropriate specialist in the
field. Patients should avoid traveling abroad for carbon ion
beam therapy without consulting a radiation oncologist, or
if it is not recommended by a multidisciplinary tumor board
that includes a radiation oncologist. There are many com-
mercial agencies advertising for and private insurance com-
panies selling insurance covering medical tourism in the
absence of medical advice. For patients with disseminated
cancer, medical tourism which requires long distance trip
may be unnecessary and may even be harmful. It may also
place the patient in a dangerous medical situation [31].
In conclusion, the launch of Korea’s nationwide ‘Right 
Decision in Cancer Care’ initiative highlights the current
agenda for cancer care that should be discussed between
physicians and patients, before any treatment decisions are
made. Cancer survival and patient-defined quality of life
should be used as one of the most important end-points to
evaluate the quality of cancer care, and treatment costs
should also be taken into consideration. Patients and physi-
cians should work together to ensure high-value care is pro-
vided and that healthcare resources are used wisely. Heal-
thcare providers and physicians need to adhere to evidence-
based practices, and policy makers should establish tools 
capable of accurately measuring value-oriented healthcare
and incentivizing high-value practices [32]. This article, as a
first step in the ‘Right Decision in Cancer Care’ initiative,
presents the initial five items on the agenda; however, the
initiative should be expanded to provide more opportunities
to correct and to prevent problems of underuse, overuse, and
misuse of finite cancer care resources, and to finally improve
the quality of cancer care in Korea.
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